A novel extracellular vesicle-engineered immunotherapy drug for Her2 breast cancer.
1/5 보강
Trastuzumab profoundly improves outcomes of Her2 breast cancer (BC) patients, but eventual drug resistance is inevitable.
APA
Lu X, Yuan W, et al. (2026). A novel extracellular vesicle-engineered immunotherapy drug for Her2 breast cancer.. Journal of advanced research. https://doi.org/10.1016/j.jare.2026.01.067
MLA
Lu X, et al.. "A novel extracellular vesicle-engineered immunotherapy drug for Her2 breast cancer.." Journal of advanced research, 2026.
PMID
41592682 ↗
Abstract 한글 요약
Trastuzumab profoundly improves outcomes of Her2 breast cancer (BC) patients, but eventual drug resistance is inevitable. Therefore, new treatment options are urgently needed. Here, we modify extracellular vesicles (EVs) with a Her2 single-chain variable fragment of trastuzumab (EVs/Her2-scFv) to target Her2 BC and found that EVs/Her2-scFv inhibit human Her2 orthotopic BC comparable to trastuzumab and also uniquely suppress brain metastasies. Moreover, EVs/Her2-scFv loaded with rabeprazole (EVs/Her2-scFv/Rabe) effectively improve tumor immunosuppressive microenvironment and abnormal vasculature of Her2 BC by reducing tumor EVs. When further anchored with CD8 T cell chemotactic CXCL9, CXCL9-loaded EVs/Her2-scFv/Rabe (EVs/Her2-scFv/CXCL9/Rabe) facilitate CD8 T cell recruitment and subsequent activation, thereby exhibiting immunotherapeutic effects on mouse Her2 BC. In BC patient-derived tumor organoids (PDOs) and peripheral blood mononuclear cell coculture systems, EVs/Her2-scFv/CXCL9/Rabe limit PDO growth by blocking Her2 signaling and activating CD8 T cells. Besides, EVs/Her2-scFv/CXCL9/Rabe are low-immunogenic with biosafety. Altogether, EVs/Her2-scFv/CXCL9/Rabe hold high potential in Her2 BC therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Activated hepatic stellate cell-derived exosomal miR-23a-3p promotes hepatocellular carcinogenesis by regulating DUSP5/ERK signaling.
- Current landscape and challenges in autologous breast reconstruction across China: A nationwide questionnaire-based survey of 198 hospitals.
- Integration of histopathological characteristics by machine learning improves the prediction of neoadjuvant immunochemotherapy response in triple-negative breast cancer.
- Histological Categorization of Desmoplastic Reaction in Triple-Negative Breast Cancer: Its Relevance to Neoadjuvant Chemoimmunotherapy Response and Tumor Biology.
- Aberrant glycosylation in hematologic malignancies: mechanisms, immune evasion, and therapeutic targeting.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence.
- Bioengineering modification and application of bacterial outer membrane vesicles.
- From feasibility to translational pathways: a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015-2025).
- Nanoluciferase-CD63 labeling reveals extracellular vesicle kinetics in a mouse intraductal model of ductal carcinoma in situ.
- Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC.
- Mitochondrial transfer in the HSC-HCC-macrophage network shapes hepatocellular carcinoma progression.